Myriad Genetics, Inc. (MYGN)
NASDAQ·Healthcare·Medical - Diagnostics & Research
$4.87
+0.83%
Mkt Cap $446.97M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 23, 2026 | $207.44M | $209.80M | +1.14% | -$0.02 | $0.04 | +300.00% | — | — |
| Q4 2025 Nov 3, 2025 | $206.96M | $205.70M | -0.61% | -$0.01 | -$0.13 | -1200.00% | — | — |
| Q3 2025 Aug 5, 2025 | $205.24M | $213.10M | +3.83% | -$0.01 | $0.05 | +600.00% | — | — |
| Q2 2025 May 6, 2025 | $211.71M | $195.90M | -7.47% | -$0.05 | -$0.03 | +40.00% | — | — |
| Q1 2025 Feb 24, 2025 | $210.35M | $210.60M | +0.12% | $0.03 | $0.03 | +0.00% | — | — |
| Q4 2024 Nov 7, 2024 | $213.56M | $213.30M | -0.12% | $0.02 | $0.06 | +215.79% | — | — |
| Q3 2024 Aug 6, 2024 | $204.95M | $211.50M | +3.20% | $0.01 | $0.05 | +509.01% | — | — |
| Q2 2024 May 7, 2024 | $193.51M | $202.20M | +4.49% | -$0.11 | -$0.01 | +90.91% | — | — |
| Q1 2024 Feb 27, 2024 | $194.78M | $196.60M | +0.93% | $0.01 | $0.04 | +214.22% | — | — |
| Q4 2023 Nov 6, 2023 | $194.03M | $191.90M | -1.10% | -$0.08 | -$0.03 | +62.50% | — | — |
| Q3 2023 Aug 3, 2023 | $187.13M | $183.50M | -1.94% | -$0.10 | -$0.08 | +20.00% | — | — |
| Q2 2023 May 3, 2023 | $171.55M | $181.20M | +5.63% | -$0.19 | -$0.21 | -10.53% | — | — |
| Q1 2023 Feb 28, 2023 | $169.47M | $177.80M | +4.91% | -$0.16 | -$0.12 | +25.00% | — | — |
| Q4 2022 Nov 1, 2022 | $170.07M | $156.40M | -8.04% | -$0.06 | -$0.19 | -216.67% | — | — |
| Q3 2022 Aug 4, 2022 | $170.96M | $179.30M | +4.88% | $0.01 | $0.04 | +300.00% | — | — |
| Q2 2022 May 5, 2022 | $156.67M | $164.90M | +5.25% | -$0.05 | -$0.03 | +40.00% | — | — |
| Q1 2022 Feb 24, 2022 | $162.96M | $160.80M | -1.32% | -$0.02 | -$0.02 | -14.29% | — | — |
| Q4 2021 Nov 2, 2021 | $166.30M | $167.30M | +0.60% | $0.01 | -$0.02 | -300.00% | — | — |
| Q3 2021 Aug 3, 2021 | $165.11M | $189.40M | +14.71% | -$0.07 | $0.12 | +271.43% | — | — |
| Q2 2021 May 3, 2021 | $156.20M | $173.10M | +10.82% | -$0.10 | -$0.06 | +40.00% | — | — |